Compare Stocks: DCOY, BOLT, ERNA, and CELZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$3.79 -1.9%	$3.87	$3.13 ▼ $7.20	$7.44M	1.09	25,193 shs	4,258 shs
CELZ Creative Medical Technology	$1.04 -3.7%	$1.02	$0.62 ▼ $6.25	$7.12M	2.04	847,765 shs	108,989 shs
DCOY Decoy Therapeutics	$2.76 +4.9%	$4.31	$2.63 ▼ $70.80	$1.72M	0.56	20,727 shs	46,687 shs
ERNA Ernexa Therapeutics	$4.02 -4.1%	$4.77	$3.18 ▼ $71.50	$6.84M	2.61	30,539 shs	15,384 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	+0.54%	-3.66%	-3.19%	-11.49%	-23.86%
CELZ Creative Medical Technology	-2.70%	-1.82%	-23.94%	-48.82%	-67.27%
DCOY Decoy Therapeutics	-4.71%	-14.05%	-33.08%	-52.95%	+262,999,900.00%
ERNA Ernexa Therapeutics	-2.78%	-3.68%	-0.48%	-33.91%	-86.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$3.79 -1.9%	$3.87	$3.13 ▼ $7.20	$7.44M	1.09	25,193 shs	4,258 shs
CELZ Creative Medical Technology	$1.04 -3.7%	$1.02	$0.62 ▼ $6.25	$7.12M	2.04	847,765 shs	108,989 shs
DCOY Decoy Therapeutics	$2.76 +4.9%	$4.31	$2.63 ▼ $70.80	$1.72M	0.56	20,727 shs	46,687 shs
ERNA Ernexa Therapeutics	$4.02 -4.1%	$4.77	$3.18 ▼ $71.50	$6.84M	2.61	30,539 shs	15,384 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	+0.54%	-3.66%	-3.19%	-11.49%	-23.86%
CELZ Creative Medical Technology	-2.70%	-1.82%	-23.94%	-48.82%	-67.27%
DCOY Decoy Therapeutics	-4.71%	-14.05%	-33.08%	-52.95%	+262,999,900.00%
ERNA Ernexa Therapeutics	-2.78%	-3.68%	-0.48%	-33.91%	-86.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.25	Hold	$14.50	283.09% Upside
CELZ Creative Medical Technology	2.00	Hold	N/A	N/A
DCOY Decoy Therapeutics	2.00	Hold	$30.00	966.10% Upside
ERNA Ernexa Therapeutics	2.00	Hold	$30.00	647.20% Upside

Current Analyst Ratings Breakdown

Latest DCOY, BOLT, ERNA, and CELZ Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/27/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CELZ Creative Medical Technology	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	BOLT Bolt Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	ERNA Ernexa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/12/2026	DCOY Decoy Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$7.70M	0.95	N/A	N/A	$13.81 per share	0.27
CELZ Creative Medical Technology	$10K	688.66	N/A	N/A	$2.04 per share	0.51
DCOY Decoy Therapeutics	N/A	N/A	N/A	N/A	$11.07 per share	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	$7.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$33.38M	-$16.44	N/A	N/A	N/A	-611.47%	-126.23%	-54.70%	11/11/2026 (Estimated)
CELZ Creative Medical Technology	-$5.99M	-$2.07	N/A	N/A	N/A	N/A	-86.52%	-81.96%	11/6/2026 (Estimated)
DCOY Decoy Therapeutics	-$12.52M	-$30.37	N/A	N/A	N/A	N/A	-315.22%	-167.15%	N/A
ERNA Ernexa Therapeutics	-$14.08M	-$14.35	N/A	N/A	N/A	N/A	-305.93%	-169.86%	11/6/2026 (Estimated)

Latest DCOY, BOLT, ERNA, and CELZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	DCOY Decoy Therapeutics	N/A	-$4.46	N/A	-$4.46	N/A	$0.23 million
8/11/2026	Q2 2026	BOLT Bolt Biotherapeutics	-$3.39	-$4.57	-$1.18	-$4.57	$0.50 million	$0.01 million
8/7/2026	Q2 2026	CELZ Creative Medical Technology	-$0.39	-$0.41	-$0.02	-$0.41	N/A	N/A
8/6/2026	Q2 2026	ERNA Ernexa Therapeutics	-$3.30	-$3.40	-$0.10	-$3.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
DCOY Decoy Therapeutics	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	1.47	2.61	2.61
CELZ Creative Medical Technology	N/A	12.90	12.90
DCOY Decoy Therapeutics	N/A	1.83	1.83
ERNA Ernexa Therapeutics	N/A	2.01	2.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
CELZ Creative Medical Technology	1.42%
DCOY Decoy Therapeutics	11.88%
ERNA Ernexa Therapeutics	70.55%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	9.40%
CELZ Creative Medical Technology	1.00%
DCOY Decoy Therapeutics	1.50%
ERNA Ernexa Therapeutics	0.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	1.93 million	1.75 million	Not Optionable
CELZ Creative Medical Technology	5	6.59 million	6.53 million	Not Optionable
DCOY Decoy Therapeutics	20	655,000	645,000	N/A
ERNA Ernexa Therapeutics	10	1.63 million	1.62 million	No Data

DCOY, BOLT, ERNA, and CELZ Headlines

Recent News About These Companies

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

August 27, 2026 | globenewswire.com

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

August 10, 2026 | globenewswire.com

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

July 24, 2026 | globenewswire.com

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)

July 15, 2026 | msn.com

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

July 15, 2026 | globenewswire.com

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

July 14, 2026 | globenewswire.com

Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosures

July 2, 2026 | tipranks.com

Eterna Therapeutics Holds 2026 Annual Stockholder Meeting

July 2, 2026 | tipranks.com

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

June 25, 2026 | globenewswire.com

Ernexa Therapeutics Inc.: Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in ...

June 17, 2026 | finanznachrichten.de

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

June 17, 2026 | globenewswire.com

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring ...

June 9, 2026 | markets.businessinsider.com

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

June 9, 2026 | globenewswire.com

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

May 27, 2026 | globenewswire.com

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

May 20, 2026 | zacks.com

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

May 20, 2026 | globenewswire.com

ERNA stock almost doubled in value today – smashing rally leads to 7 trading halts

May 14, 2026 | msn.com

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

May 11, 2026 | globenewswire.com

Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

May 7, 2026 | finanznachrichten.de

Ernexa stock surges 40% on ovarian cancer trial results

May 6, 2026 | au.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DCOY, BOLT, ERNA, and CELZ Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$3.78 -0.08 (-1.94%)

Closing price 03:58 PM Eastern

Extended Trading

$3.77 -0.02 (-0.40%)

As of 07:30 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Creative Medical Technology NASDAQ:CELZ

$1.04 -0.04 (-3.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 +0.02 (+2.31%)

As of 07:58 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Decoy Therapeutics NASDAQ:DCOY

$2.76 +0.13 (+4.94%)

Closing price 04:00 PM Eastern

Extended Trading

$2.77 +0.01 (+0.36%)

As of 07:37 PM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Ernexa Therapeutics NASDAQ:ERNA

$4.02 -0.17 (-4.06%)

Closing price 04:00 PM Eastern

Extended Trading

$4.08 +0.07 (+1.62%)

As of 07:49 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DCOY, BOLT, ERNA, and CELZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DCOY, BOLT, ERNA, and CELZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DCOY, BOLT, ERNA, and CELZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DCOY, BOLT, ERNA, and CELZ Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Creative Medical Technology NASDAQ:CELZ

Decoy Therapeutics NASDAQ:DCOY

Ernexa Therapeutics NASDAQ:ERNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DCOY, BOLT, ERNA, and CELZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DCOY, BOLT, ERNA, and CELZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DCOY, BOLT, ERNA, and CELZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DCOY, BOLT, ERNA, and CELZ Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Creative Medical Technology NASDAQ:CELZ

Decoy Therapeutics NASDAQ:DCOY

Ernexa Therapeutics NASDAQ:ERNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools